Infinity Pharmaceuticals, Inc.
INFIQ · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $3 | $2 | $2 | $3 |
| % Growth | 39.6% | 8.1% | -43.6% | – |
| Cost of Goods Sold | $2 | $1 | $1 | $7 |
| Gross Profit | $1 | $1 | $1 | -$4 |
| % Margin | 39.7% | 39.7% | 39.7% | -139.7% |
| R&D Expenses | $32 | $32 | $27 | $27 |
| G&A Expenses | $13 | $14 | $12 | $14 |
| SG&A Expenses | $13 | $14 | $12 | $14 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $46 | $46 | $39 | $41 |
| Operating Income | -$45 | -$45 | -$38 | -$46 |
| % Margin | -1,729.4% | -2,426.4% | -2,239.5% | -1,497.7% |
| Other Income/Exp. Net | $0 | -$0 | -$2 | -$1 |
| Pre-Tax Income | -$44 | -$45 | -$40 | -$47 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$44 | -$45 | -$40 | -$47 |
| % Margin | -1,711.1% | -2,436.1% | -2,355.6% | -1,543.4% |
| EPS | -0.5 | -0.53 | -0.68 | -0.83 |
| % Growth | 5.7% | 22.1% | 18.1% | – |
| EPS Diluted | -0.5 | -0.53 | -0.68 | -0.83 |
| Weighted Avg Shares Out | 89 | 86 | 60 | 57 |
| Weighted Avg Shares Out Dil | 89 | 86 | 60 | 57 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $2 | $3 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$44 | -$45 | -$38 | -$44 |
| % Margin | -1,686.5% | -2,400.5% | -2,185.2% | -1,453.9% |